linjc16/ctgov huggingface dataset:
Erectile Dysfunction in Severe Obstructive Sleep Apnea: Effects of CPAP Therapy

Study Overview
=================
Brief Summary
-----------------
Obstructive sleep apnea has been linked to erectile dysfunction. Furthermore, small studies suggest that treatment of sleep apnea by continuous positive airway pressure (CPAP) may reverse erectile dysfunction in affected patients. The present study aims to investigate in a larger cohort if severe sleep apnea is independently associated with erectile dysfunction and if 6-12 months of CPAP therapy lead to an improvement of erectile dysfunction.

Official Title
-----------------
Erectile Dysfunction in Severe Obstructive Sleep Apnea : Effects of CPAP Therapy

Conditions
-----------------
Obstructive Sleep Apnea, Erectile Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: apnea-hypopnea-index > 30/h no CPAP therapy male gender 18-80 years of age having or attempting to have regular sexual intercourse Exclusion Criteria: apnea-hypopnea-index < 30/h already treated by CPAP female gender age < 18 or > 80 years not having or not attempting to have regular sexual intercourse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of erectile function in severe sleep apnea after 6-12 months of CPAP therapy | an established self-administered questionnaire is used to assess changes in erectile function occurring after 6-12 months of CPAP therapy in patients with severe sleep apnea | at the time of diagnosis of sleep apnea and after 6-12 months of CPAP therapy |
Tubeless Intersegmentectomy Plane Identification With Fluorography

Study Overview
=================
Brief Summary
-----------------
Background: We aimed to evaluate the combination of inflation- deflation method and fluorography with the ICG injection in the tubeless minimally invasive segmentectomy (no intubation, VATS or Robotic). Methods: A one- armed, prospective randomized controlled study was designed. The intersegmental plane was not so clear during the tubeless minimally invasive segmentectomy, and the presentation of the plane sometimes cost more time. This study will evaluate consecutive patients with the combination of inflation- deflation method and fluorography with the ICG injection.

Official Title
-----------------
Tubeless Intersegmentectomy Plane Identification With Inflation- Deflation Line Combined With Fluorography

Conditions
-----------------
Operation Time, Postoperative Complications

Intervention / Treatment
-----------------
* Procedure: inflation- deflation line combined with ICG fluorography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cardio- pulmonary function can tolerate the minimally invasive surgery (including VATS and robotic surgery); benign pulmonary lesion considering for segmentectomy; ≤2cm pulmonary adenocarcinoma with ground- glass components, considering for segmentectomy. Exclusion Criteria: cardio- pulmonary function can not tolerate the minimally invasive surgery (including VATS and robotic surgery); segmentectomy is not considered as the surgery plan.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: inflation- deflation line combined with ICG fluorography<br>Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless | Procedure: inflation- deflation line combined with ICG fluorography<br>* Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time of description and management of the intersegmental plane | time of description and management of the intersegmental plane | during surgery | 
| perioperative complication rate | perioperative complication rate | within 7 days after surgery | 
| incisal margin of the tumor | incisal margin of the tumor | during surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease- free survival | DFS | within 5 years after surgery |
The Effect of Ulnar Nerve Injury Localization on Sleep Quality in Patients With Ulnar Nerve Entrapment Neuropathy

Study Overview
=================
Brief Summary
-----------------
Regardless of the cause of ulnar nerve entrapment neuropathy, we are planning to investigate the relationship between sleep quality disorder that may develop due to ulnar neuropathy and the level of entrapment in electromyelography.

Official Title
-----------------
The Effect of Ulnar Nerve Injury Localization on Sleep Quality in Patients With Ulnar Nerve Entrapment Neuropathy

Conditions
-----------------
Ulnar Neuropathies

Intervention / Treatment
-----------------
* Diagnostic Test: EMG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: having ulnar nerve entrapment neuropathy with clinical examination and EMG (electroneuromyography) to be between the ages of 18-65 be give informed consent Exclusion Criteria: malignancy surgical history in the ipsilateral upper extremity sleep apnea narcolepsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Electromyelography<br>EMG will be performed only once to determine the ulnar nerve entrapment site in patients. | Diagnostic Test: EMG<br>* Electromyelography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pittsburg Sleep Quality Index | sleep evaluation between 0 and 21 points, higher scores mean a worse outcome. | 10 minutes. |
Surviving Pneumonia

Study Overview
=================
Brief Summary
-----------------
The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. The main clinical outcomes of the study consist of deaths and development of diabetes.

Official Title
-----------------
Surviving Pneumonia

Conditions
-----------------
Community-acquired Pneumonia

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infiltrate on chest radiograph plus one or more of the following: Fever (temperature, ≥38.0°C) Hypothermia (<35.0°C), New cough with or without sputum production Pleuritic chest pain Dyspnea Altered breath sounds on auscultation. Exclusion Criteria: Patients unable to give informed consent Patients unwilling to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Community-acquired pneumonia<br>Adults over 18 years old admitted with confirmed community-acquired pneumonia. | Other: No intervention<br>* Obervational<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of death from any causes | Assessed through patient files | From date of admission until the day of death from any causes, up to 24 months | 
| Number of participants who develop diabetes | Assessed through patient files and the national registers | Up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of hospital stay | Through patient files | Participants will be followed for the duration of hospital stay, an expected average of 5 days | 
| Oral glucose tolerance test |  | Day 1, discharge (an average of 5 days), 1 month and 6-month | 
| Number of participants who are readmitted | Through patient files | Up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Community-acquired pneumonia, Diabetes, Immune status, Nutritional status, Physical inactivity, Risk factors
Accuracy of Computer Guided Free Gingival Graft

Study Overview
=================
Brief Summary
-----------------
A patient specific surgical guide for harvesting of free gingival graft from the palate

Official Title
-----------------
Accuracy of Computer Guided Free Gingival Graft

Conditions
-----------------
Computer Guided, Free Gingival Graft

Intervention / Treatment
-----------------
* Other: patient specific guide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with intraoral alveolar defect requiring soft tissue augmentation Exclusion Criteria: - patients with systemic diseases interfering with surgical interventions - Poor oral hygiene

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study group<br>the patients undergo free gingival graft harvest from the palate using a patient specific guide | Other: patient specific guide<br>* harvesting palatal free gingival graft using the patient specific guide<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of the guide | accuracy of the predefined graft dimensions relative to the required dimensions of the recipient site in millimetres | One month |
Efficacy and Acceptability of a Monkeypox Curriculum for Disproportionately Impacted Communities

Study Overview
=================
Brief Summary
-----------------
The study team will create an online module via the REDCap platform. The module will include around 5 videos and several infographics covering the topics of symptoms, transmission, prevention, vaccination, and treatment of the monkeypox virus. Surveys assessing the primary and secondary study endpoints will be given to participants before and after the module. The purpose of the study is to assess the efficacy and acceptability of an educational presentation on monkeypox in a cohort of individuals recruited from Rainbow Health and to secondarily assess participant risk perception, intention to vaccinate, and confidence in public health initiatives.

Official Title
-----------------
Efficacy and Acceptability of a Monkeypox Curriculum for Disproportionately Impacted Communities

Conditions
-----------------
Monkey Pox

Intervention / Treatment
-----------------
* Other: Online module


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals who are 18 years and older Individuals able to read and write in English Exclusion Criteria: Unable to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Online module|online module including around 5 videos and several infographics covering the topics of symptoms transmission, prevention, vaccination, and treatment of the monkeypox virus.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of intervention | Efficacy of intervention will be measured by changes in knowledge using a survey | baseline | 
| Efficacy of intervention | Efficacy of intervention will be measured by changes in knowledge using a survey | immediately after intervention | 
| Acceptability | Acceptability will be measured by a validated questionnaire based on the Theoretical Framework of Acceptability. | immediately after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk perception | questionnaire | baseline | 
| risk perception | questionnaire | immediately after intervention | 
| intention to vaccinate | questionnaire | baseline | 
| intention to vaccinate | questionnaire | immediately after intervention | 
| confidence in public health initiatives | questionnaire | baseline | 
| confidence in public health initiatives | questionnaire | immediately after intervention |
Chronic Obstructive Pulmonary Disease (COPD) Nutrition Support Trial

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the best form of dietary intervention to undernourished individuals with COPD. The research aims to test the null hypothesis that there is no difference between oral nutritional supplements and dietary advice.

Official Title
-----------------
A Randomised Trial of Oral Nutritional Supplements Versus Dietary Advice on Clinical Outcomes in Patients With COPD

Conditions
-----------------
Malnutrition

Intervention / Treatment
-----------------
* Dietary Supplement: Oral Nutritional Supplements (Fortisip)
* Other: Dietary Advice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female Age >18 years At risk of malnutrition Competent to provide written informed consent and able to answer questions Able to eat and drink Willingness to take part in the trial and to follow the trial protocol FEV1 <80% predicted and FEV1/FVC <0.7 Exclusion Criteria: Requirement for tube or parenteral nutrition Galactosemia Receiving current oral nutritional supplementation Palliative care Chronic renal disease requiring dialysis Liver failure Malignancy Participation in other studies Bronchiectasis Those already under the care of a dietitian

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Dietary Advice | Other: Dietary Advice<br>* Standard dietary advice<br>|
| Other: 2<br>Supplements | Dietary Supplement: Oral Nutritional Supplements (Fortisip)<br>* These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome measure is Quality of Life |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nutrition, COPD
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

Study Overview
=================
Brief Summary
-----------------
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.

Official Title
-----------------
A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Drug: Farydak


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to provide written informed consent At least 18 years of age Clinical diagnosis of multiple myeloma that meets published diagnostic criteria Initiating panobinostat within 60 days of enrollment ECOG performance status 0-1 Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response Willing and able to complete the PRO questionnaire Exclusion Criteria: Diagnosed with any B-cell malignancy other than myeloma Estimated life expectancy <6 months Currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Farydak|non-interventional study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response to treatment | Looking for patient reproted response to treatment with panobinostat | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Farydak, panobinostat
Effect of Flaxseed on Lipid Uptake and Appetite

Study Overview
=================
Brief Summary
-----------------
Randomized trial to test the effect of flaxseed fractions on appetite regulation and intestinal lipid absorption.

Detailed Description
-----------------
Randomized multiple crossover trial in 18 healthy males aged 18 to 40 years each are required to complete a total of five iso-caloric meal tests lasting approximately 8½ hours. Test meals will be given as breakfast meals, in which different fractions of flaxseeds are incorporated into baked products. Appetite will be registered using visual analogue scales during 7 hours after the test meal and a total of 10 blood samples will be drawn to evaluate TAG in chylomicrons, plasma LDL, HDL and total cholesterol, plasma TAG, insulin, glucose and appetite hormone levels. At the end of the test day an ad libitum meal will be served and food intake registered.

Official Title
-----------------
Effect of Whole Flaxseeds and Flaxseed Mucilage on Lipid Absorption, Glucose and Insulin Metabolism and Appetite Regulation

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Dietary Supplement: Whole flaxseeds, flaxseed mucilage, glucomannan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males aged 18-40 years Normal weight or moderately overweigh (BMI 25-30 kg/m2) Exclusion Criteria: Blood drawing/donation less than six months prior to start of the study Hemoglobin concentration <8mmol/L Chronic diseases (i.e. diabetes, CVD), hypertension, hyperlipidemia Consumption of dietary supplements including vitamin tablets Smoking Excess physical activity (>10h of intense physical activity per week) Medicine use (not including occasional consumption of pain killers)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: Whole flaxseeds, flaxseed mucilage, glucomannan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TAG in chylomicrons |  |  | 
| serum TAG |  |  | 
| HDL, LDL and total cholesterol |  |  | 
| appetite scores |  |  | 
| ad libium food intake |  |  | 
| appetite hormone levels |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| free fatty acid profile |  |  | 
| plasma glucose |  |  | 
| plasma insulin |  |  | 
| meal macronutrient composition |  |  | 
| meal energy content |  |  | 
| meal pleasantness |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fat absorption, fibres